Lunamed Operations 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases  1 Product   1 Trial   25 News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lunaphen (4 Phenyl butyrate prolonged-release) / Lunamed Operations
2010-020681-16: A PILOT STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND EFFICACY OF A DAILY DOSE OF 500MG. LU901 (4PHENYL-BUTYRATE, CONTROLLED RELEASE TABLETS) IN ADDITION TO STANDARD HORMONAL TREATMENT IN PATIENTS WITH METASTASIZED PROSTATE CARCINOMA AND A LIFE EXPECTANCY OF AT LEAST 6 MONTHS.

Ongoing
2
30
Europe
4 Phenyl-butyrate, LU901,
Lunamed Operations AG
Patients suffering from prostate carcinoma with progression underfirst line hormonal treatment. Patients entering the study shouldhave a life expectancy prognosis of at least 6 months.
 
 

Download Options